Download Unicorn Signals App

Powered By EquityPandit
Latest News

Cipla receives USFDA approval for generic Dacogen

Cipla has received final approval for generic version of Dacogen, from the US health regulator, which is suggested for treatment of myelodysplastic syndromes.

Cipla in a BSE filing said, “it has received final approval for its abbreviated new drug application (ANDA) for Decitabine Injection 50 mg single-use sterile vial from the United States Food and Drug Administration (USFDA).”

Further, the product which has received approval is a generic equivalent of Otsuka America Pharmaceutical Inc’s Dacogen and it is available for shipping immediately.

Read EquityPandit’s Technical Analysis on Cipla

Get Daily Prediction & Stocks Tips On Your Mobile